Alpha-1-proteinase inhibitor human

FDA label, CSL Behring LLC, effective 2010-09-29. Full label on DailyMed

Package labels

Loading package label images…

Patient handout

Looking up MedlinePlus…

From MedlinePlus, U.S. National Library of Medicine

Specialty pharmacy: therapy management checklist, storage and cold chain, dosing calendar, Medicare Part D coverage.

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using.

Dosing in kidney impairment

This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.

Preparation and administration

Prepare this dose

Your numbers for alpha-1-proteinase inhibitor human. Take vial strength, diluent, and limits from the label below.

Basis

Enter a dose to see draw volume, final concentration, and rates.

When reconstituted as directed, Zemaira ® may be administered intravenously at a rate of approximately 0.08 mL/kg/min as determined by the response and comfort of the patient. The recommended dosage of 60 mg/kg body weight will take approximately 15 minutes to infuse. Preparation Each product package contains one Zemaira ® single use vial, one 20 mL vial of Sterile Water for Injection, USP (diluent) and one color-coded vented transfer device with air inlet filter.

Administer within three hours after reconstitution. Reconstitution 1. Bring both product (green cap) vial and diluent (white cap) vial to room temperature prior to reconstitution. 2. Remove the plastic flip-top caps from the vials. Aseptically cleanse the rubber stoppers with antiseptic solution and allow them to dry. [See table below.] 3.

Allow the vacuum in the Zemaira ® vial to pull the diluent into the Zemaira ® vial. 6. During diluent transfer, wet the lyophilized cake completely by gently tilting the Zemaira ® vial. (Fig. 4) Do not allow the air inlet filter to face downward. Care should be taken not to lose the vacuum, as this will prolong reconstitution of the product. 7.

Gently swirl the Zemaira ® vial until the powder is completely dissolved. (Fig. 5) DO NOT SHAKE . 9. Inspect parenteral drug products visually for particulate matter and discoloration prior to administration. Administer at room temperature within three hours after reconstitution. Fig. 2 Fig. 3 Fig. 4 Fig. 5 Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Pooling Reconstituted Vials If more than one vial of Zemaira ® is needed to achieve the required dose, use an aseptic technique to transfer the reconstituted solution from the vials into the administration container (e.g., empty I.V. bag or glass bottle).

Administration Parenteral drug preparations should be inspected visually for particulate matter and discoloration prior to administration. Administer at room temperature within three hours after reconstitution. Filter the reconstituted solution during administration. To ensure proper filtration of Zemaira ® , use an I.V. administration set with a suitable 5 micron infusion filter (not supplied).

Follow the appropriate procedure for I.V. administration. After administration, any unused solution and administration equipment should be discarded in accordance with biohazard procedures.

NOTE: The transfer device (Fig. 1) provided in the package is comprised of a white (diluent) end, which has a double orifice, and a green (product) end, which has a single orifice. Incorrect use of the transfer device will result in loss of vacuum and prevent transfer of the diluent, thereby preventing reconstitution of the product.
Fig. 1
The transfer device is sterile. Do not touch the exposed ends of the spike after removing the protective covers.

Drug interactions

Check interactions

Add the patient's other drugs. Matches come from both FDA labels: by name, drug class, and enzyme or transporter pathway.

  • Alpha-1-proteinase inhibitor human

Contraindications

Zemaira ® is contraindicated in individuals with a known hypersensitivity to any of its components. Zemaira ® is also contraindicated in individuals with a history of anaphylaxis or severe systemic response to A 1 -PI products. Zemaira ® is contraindicated in IgA deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.

Safety data

Reported adverse events (FAERS)

Loading
Source: FDA Adverse Event Reporting System via openFDA

Liver injury (LiverTox)

LiverTox has no chapter for alpha-1-proteinase inhibitor human. Check the label's hepatic warnings.

Pregnancy and lactation

Pregnancy

Pregnancy Category C Animal reproduction studies have not been conducted with Zemaira ® . It is also not known whether Zemaira ® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Zemaira ® should be given to a pregnant woman only if clearly needed.

Lactation

Nursing Mothers It is not known whether Zemaira ® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Zemaira ® is administered to a nursing woman.

For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.

Supply and cost

Drug shortage status

Loading

Recalls (last 24 months)

Loading

Therapeutic equivalence (Orange Book)

Loading

Price ladder

Not the price at the counter
Loading

These are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.

Products and NDCs

Loading

Recruiting clinical trials

Loading